Neutralizing antibodies against the drug that do not affect efficacy are probably inconsequential. On the other hand, neutralizing antibodies against native GLP-1 or GIP could be problematic insofar as these pathways modulate various metabolic processes, and the nAbs might persist even after a patient discontinues drug treatment.
Market Data 
Markets 
AI
